GeneDx to enter ‘attractive’ market with prenatal test, says Canaccord

Canaccord maintains a Buy rating and $170 price target on shares of GeneDx (WGS) after the company announced GenomeDx Prenatal, a phenotype-informed, trio-based test intended for pregnancies with fetal anomalies identified through ultrasound, which will be available for order beginning in February. GenomeDx Prenatal is differentiated given it is whole genome sequencing-based and positions GeneDx to effectively enter an attractive market, the analyst tells investors in a research note.